Kinnate Biopharma CEO Nima Farzan on cancer Covid vaccines and agility – San Francisco Business Times

Kinnate Biopharma CEO Nima Farzan on cancer Covid vaccines and agility – San Francisco Business Times

Summary : Cerberus cashes out of Peninsula vaccine maker in $270 million deal

How this spinout from research deal aims to drug the undruggable

Bulk of genetic testing company’s 1,000 layoffs will be in S.F.

Cerberus cashes out of Peninsula vaccine maker in $270 million deal

How this spinout from research deal aims to drug the undruggable

Bulk of genetic testing company’s 1,000 layoffs will be in S.F.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *